胰岛素瘤 中国就医指南

Insulinoma is a rare, typically benign neuroendocrine tumor of the pancreatic beta cells that secretes excessive and unregulated insulin, leading to recurrent episodes of hypoglycemia. It is the most common functional pancreatic neuroendocrine tumor (pNET), accounting for approximately 1–2% of all pancreatic tumors. Pathogenically, insulinomas arise from clonal proliferation of insulin-producing beta cells, often with somatic mutations in genes such as YY1, TSC2, or mTOR pathway regulators; unlike many endocrine tumors, they rarely harbor MEN1 mutations unless associated with multiple endocrine neoplasia type 1 syndrome. The autonomous insulin hypersecretion suppresses counter-regulatory hormones (e.g., glucagon, epinephrine) and impairs hepatic glucose production, resulting in fasting or postprandial hypoglycemia. Symptoms are predominantly neuroglycopenic (confusion, visual disturbances, seizures, loss of consciousness) or adrenergic (sweating, tremor, palpitations, anxiety). Diagnosis hinges on biochemical confirmation—documenting low plasma glucose (<50 mg/dL) with inappropriately elevated insulin (>3 µU/mL), C-peptide (>0.6 ng/mL), and proinsulin levels during spontaneous or provoked hypoglycemia—followed by precise anatomical localization via contrast-enhanced CT, MRI, or functional imaging (e.g., Ga-68 DOTATATE PET/CT). Epidemiologically, insulinomas affect approximately 1–4 individuals per million annually, with peak incidence between ages 40–60 and slight female predominance (F:M ≈ 1.5:1). Most cases are sporadic and solitary; <10% are malignant (defined by metastasis or local invasion), and <5% occur in familial syndromes like MEN1. Risk factors are poorly defined but include germline MEN1 mutations, prior abdominal radiation (rare), and possibly chronic pancreatitis—though no strong environmental or lifestyle associations exist. Quality of life is significantly impaired: patients experience unpredictable neurocognitive dysfunction, driving restrictions, occupational limitations, anxiety about hypoglycemic emergencies, and social withdrawal. Untreated, severe hypoglycemia may cause permanent neurological injury or sudden death. Even after successful resection, up to 15% report persistent fatigue or cognitive complaints, underscoring the need for multidisciplinary follow-up involving endocrinology, surgery, and neuropsychology. Early diagnosis and definitive surgical enucleation remain the cornerstone of management, offering cure in >90% of benign cases.

# 胰岛素瘤治疗方案与费用明细（内分泌科）

一、非手术治疗（适用于无法耐受手术、术前准备或术后复发高风险者）

• •药物控制：二氮嗪（5–10 mg/kg/d，口服）+ 普萘洛尔（缓解心悸），月药费 800–2,500元；
• •营养支持与血糖监测：动态血糖监测（CGM）系统（7天）+ 频繁指尖血糖检测，月耗材及检查费 1,200–3,000元；
• •术前评估检查：72小时饥饿试验、胰岛素/C肽/血糖同步测定、腹部增强MRI+超声内镜（EUS），合计 4,800–7,200元。

二、手术治疗（根治首选，适用于定位明确、无远处转移者）

• •腹腔镜胰体尾切除术（最常用）：术前EUS+CT双重定位，术中术中超声引导，住院7–10天，总费用 68,000–95,000元（含术前检查 5,000–6,500元）；
• •开腹局部剜除术（保留胰腺功能）：适用于单发小瘤（<2 cm）、位于胰头/钩突者，总费用 72,000–102,000元。

三、特殊复杂情况处理

• •多发性/转移性/恶性胰岛素瘤（伴肝转移）：联合肝动脉栓塞（TACE）+ 长效奥曲肽（LAR）+ 肽受体放射治疗（PRRT），年治疗费 280,000–450,000元；
• •难治性低血糖昏迷反复发作：需ICU监护、静脉葡萄糖泵控糖及神经功能评估，单次住院费用 15,000–32,000元。

四、方案快速选择指南

✅ 首选手术者：年轻、单灶、影像定位清晰 → 选腹腔镜剜除术（性价比最优）； ✅ 高龄/合并严重心肺疾病者：以二氮嗪+CGM为主，年均支出约 3.5–6万元； ✅ 恶性转移患者：转至内分泌肿瘤MDT团队，启动PRRT联合靶向治疗。

> 所有费用依据2024年北京协和医院、上海瑞金医院、广州中山一院等公立三甲内分泌科实际收费区间核定（RMB）。